The Asian Scientist 100
Di Li
Institution
National Astronomical Observatories of the Chinese Academy of Sciences
Country
China
Field
Aerospace & Astronomy
Li received the Marcel Grossmann Award for his pioneering contributions in the field of fast radio bursts. Li is the first scientist in China to receive this prize for research conducted within China.
(Photo: The Paper)
AWARDS
- Marcel Grossmann Award
Related articles
ADB Loans Indonesia US$100 Million For Sanitation & Infrastructure Projects
The Asian Development Bank will lend Indonesia US$100 million to finance basic infrastructure projects in rural villages.
Folate Intake May Lower Breast Cancer Risk In Premenopausal Women
A US-China joint study has shown that folate intake reduces the risk of breast cancer in premenopausal women by 40 percent.
Kyowa Kirin Starts Phase III Trial Of ARQ197/Erlotinib In NSC Lung Cancer
Kyowa Hakko Kirin is starting a Phase III trial evaluating the combination of ARQ 197 (tivantinib) and erlotinib in Asia for patients with advanced or metastatic non-small cell lung cancer.
Older New Zealanders Underestimate Their Risk Of Deadly Skin Cancer
New Zealanders aged 60 and over falsely believe they are at low risk of the fatal skin cancer melanoma, according to a new study.
Study: Blocking Clathrin May Inhibit Viral Entry Into Cells
Researchers have developed a technique to stop viruses and bacteria from entering cells by blocking a key protein called clathrin, paving the way for new drugs to treat infections.
Blind New Zealanders Face Body Clock Battle
Nearly 3,000 blind and partially-sighted New Zealanders could be suffering from undiagnosed sleep timing disorders, according to a recent study from The University of Auckland.
Study: Smokers Who Take Multivitamins End Up Smoking More Cigarettes
A new study in Taiwan reveals that smokers who take multivitamins offset their healthy behavior by smoking more cigarettes.
Drug From New Zealand Kills Cancer Cells By Starving Them Of Glucose
Scientists at the University of Auckland in New Zealand have designed a new compound that starves certain cancer cells of glucose, depriving them of energy and causing them to die.
Amylin and Takeda Discontinue Phase II Obesity Drug Combination Therapy
Amylin and Takeda announced yesterday that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity.